Article | Published:

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models

Nature Medicine volume 24, pages 194202 (2018) | Download Citation

Abstract

The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine. However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date. The neutral amino acid glutamine serves as a key intermediate in numerous metabolic processes leveraged by cancer cells, including biosynthesis, cell signaling, and oxidative protection. Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2. Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated cancer cell growth and proliferation, increased cell death, and increased oxidative stress, which collectively contributed to antitumor responses in vitro and in vivo. This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

References

  1. 1.

    , , & Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. Front. Chem. 2, 61 (2014).

  2. 2.

    , & Glutaminolysis as a target for cancer therapy. Oncogene 35, 3619–3625 (2016).

  3. 3.

    et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin. Cancer Res. 19, 560–570 (2013).

  4. 4.

    et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35, 3201–3208 (2016).

  5. 5.

    et al. Non-invasive glutamine PET reflects pharmacological inhibition of BRAFV600Ein vivo. Mol. Imaging Biol. 19, 421–428 (2017).

  6. 6.

    et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762–765 (2009).

  7. 7.

    et al. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur. J. Cancer 47, 1946–1954 (2011).

  8. 8.

    et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362–1368 (2017).

  9. 9.

    et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-henylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 55, 10551–10563 (2012).

  10. 10.

    et al. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J. Clin. Oncol. 33, 2512 (2015).

  11. 11.

    et al. Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism. Gastroenterology 118, 90–100 (2000).

  12. 12.

    et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122, 3521–3532 (2013).

  13. 13.

    , , , & 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel scaffold for inhibition of ASCT2-mediated glutamine transport. Bioorg. Med. Chem. Lett. 26, 1044–1047 (2016).

  14. 14.

    , & Nγ-Aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg. Med. Chem. 13, 1111–1118 (2005).

  15. 15.

    et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 106, 21984–21989 (2009).

  16. 16.

    et al. Structure and allosteric inhibition of excitatory amino acid transporter 1. Nature 544, 446–451 (2017).

  17. 17.

    & Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 15, 254–266 (2005).

  18. 18.

    et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521–534 (2009).

  19. 19.

    & Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112–1116 (2006).

  20. 20.

    T cell Myc-tabolism. Immunity 35, 845–846 (2011).

  21. 21.

    & Multiphoton redox ratio imaging for metabolic monitoring in vivo. Methods Mol. Biol. 594, 155–162 (2010).

  22. 22.

    et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 74, 5184–5194 (2014).

  23. 23.

    , , & Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54–61 (2008).

  24. 24.

    , & The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim. Biophys. Acta 1800, 80–95 (2010).

  25. 25.

    , , & Programmed cell death induced by ceramide. Science 259, 1769–1771 (1993).

  26. 26.

    , , , & A UDP-glucose derivative is required for vacuolar autophagic cell death. Autophagy 4, 680–691 (2008).

  27. 27.

    et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol. 8, 831–838 (2012).

  28. 28.

    , & The role of lipids in the control of autophagy. Curr. Biol. 23, R33–R45 (2013).

  29. 29.

    , , & Complex relations between phospholipids, autophagy, and neutral lipids. Trends Biochem. Sci. 41, 907–923 (2016).

  30. 30.

    , , , & Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int. J. Clin. Exp. Pathol. 7, 1093–1100 (2014).

  31. 31.

    et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293–2306 (2015).

  32. 32.

    et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981–8987 (2010).

  33. 33.

    et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890–901 (2014).

  34. 34.

    et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 107, 7461–7466 (2010).

  35. 35.

    et al. GPNA inhibits the sodium-independent transport system L for neutral amino acids. Amino Acids 49, 1365–1372 (2017).

  36. 36.

    , , , & 3′-Deoxy-3′-[18F]-fluorothymidine PET imaging reflects PI3K–mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One 9, e108193 (2014).

  37. 37.

    , & Role of PRAS40 in Akt and mTOR signaling in health and disease. Am. J. Physiol. Endocrinol. Metab. 302, E1453–E1460 (2012).

  38. 38.

    et al. The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways. Exp. Cell Res. 342, 113–124 (2016).

  39. 39.

    et al. L-Glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am. J. Physiol. 272, G943–G953 (1997).

  40. 40.

    & ROSETTALIGAND: protein–small molecule docking with full side-chain flexibility. Proteins 65, 538–548 (2006).

  41. 41.

    et al. Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. USA 108, 6235–6240 (2011).

  42. 42.

    et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res. 17, 3332–3340 (2011).

Download references

Acknowledgements

The authors acknowledge M. Tantawy for assistance with PET imaging, F. Revetta for histology expertise, and A. Rosenberg and A. Cohen for helpful discussions and editorial assistance. The authors wish to acknowledge research support from the Vanderbilt Ingram Cancer Center Support Grant (National Institutes of Health (NIH) National Cancer Institute (NCI) P30CA068485, H.C.M.), which supports the Vanderbilt-Ingram Cancer Center (VICC) Chemical Synthesis Core, Vanderbilt University Medical Center (VUMC) Radiochemistry Core, and Center for Small Animal Imaging; the Kleberg Foundation (H.C.M.); a Vanderbilt Trans-Institutional Program (TIPS) Award to the Vanderbilt Center for Molecular Probes (H.C.M.); the Vanderbilt Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer (NIH NCI P50CA095103, R.J.C. and H.C.M.); an Outstanding Investigator Award from the NCI (R35CA197570, R.J.C.); and the Vanderbilt Digestive Disease Research Center (NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK058404, H.C.M.).

Author information

Author notes

    • Melissa C Skala

    Present address: Morgridge Institute for Research, Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, Wisconsin, USA.

Affiliations

  1. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Michael L Schulte
    • , Allie Fu
    • , Ping Zhao
    • , Jun Li
    • , Ling Geng
    • , Shannon T Smith
    • , Michael L Nickels
    •  & H Charles Manning
  2. Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Michael L Schulte
    • , Michael L Nickels
    •  & H Charles Manning
  3. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Michael L Schulte
    • , Michael L Nickels
    •  & H Charles Manning
  4. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Jumpei Kondo
    •  & Robert J Coffey
  5. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Robert J Coffey
    • , Jordan Berlin
    • , M Kay Washington
    •  & H Charles Manning
  6. Veterans Health Administration, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.

    • Robert J Coffey
  7. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • Marc O Johnson
    • , Jeffrey C Rathmell
    •  & M Kay Washington
  8. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.

    • Joe T Sharick
    • , Melissa C Skala
    •  & H Charles Manning
  9. Vanderbilt Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.

    • Jarrod A Smith
  10. Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA.

    • Jarrod A Smith
  11. Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    • H Charles Manning
  12. Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.

    • H Charles Manning

Authors

  1. Search for Michael L Schulte in:

  2. Search for Allie Fu in:

  3. Search for Ping Zhao in:

  4. Search for Jun Li in:

  5. Search for Ling Geng in:

  6. Search for Shannon T Smith in:

  7. Search for Jumpei Kondo in:

  8. Search for Robert J Coffey in:

  9. Search for Marc O Johnson in:

  10. Search for Jeffrey C Rathmell in:

  11. Search for Joe T Sharick in:

  12. Search for Melissa C Skala in:

  13. Search for Jarrod A Smith in:

  14. Search for Jordan Berlin in:

  15. Search for M Kay Washington in:

  16. Search for Michael L Nickels in:

  17. Search for H Charles Manning in:

Contributions

M.L.S. performed or designed most of the experiments with assistance from A.F., L.G., P.Z., and J.L. S.T.S. and J.A.S. performed computational modeling. J.K. and R.J.C. performed organoid studies. J.B. enrolled individuals who provided tissues for organoids and PDXs. J.T.S. and M.C.S. performed optical redox ratio measurements. M.O.J. and J.C.R. performed T cell experiments. M.K.W. interpreted pathology samples. M.L.N. oversaw radiopharmaceutical production and provided technical assistance. H.C.M. designed and supervised the study. M.L.S., M.L.N., and H.C.M. wrote the manuscript. All authors edited and approved the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to H Charles Manning.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–21

  2. 2.

    Life Sciences Reporting Summary

Excel files

  1. 1.

    Supplementary Data 1

    Full in vivo metabolomic data set

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4464

Further reading